Quarterly figures - Schott Pharma increases sales despite low capacity utilization
Despite a recent low capacity utilization in the important business with glass vials for medicines or vaccines, Schott Pharma has increased its turnover. The Mainz-based company reported sales of around 899 million euros in the twelve months to the end of September, as the company announced on Tuesday. This was around nine percent more than in the previous year. The company, which manufactures syringes and ampoules for the pharmaceutical and biotech industries, among other things, will present its full financial results on January 26.
The low capacity utilization in the second half of the financial year was due to customers reducing their inventories. Nevertheless, the company sees growth potential in areas such as packaging for mRNA-based drugs. Schott's pharmaceutical division, which was spun off in 2022, recently expanded its production capacities in Müllheim in Baden-Württemberg - including new production lines for prefillable polymer syringes. These syringes are intended for medicines that need to be stored and transported at low temperatures.
Schott Pharma went public on the Frankfurt Stock Exchange in the fall. Since Monday, the shares have been part of the SDax, the index of smaller stocks.
Read also:
- A clan member is punished here
- Traffic lawyer warns: Don't talk to the police!
- Will he be convicted as Jutta's murderer after 37 years?
- He also wanted to kill his cousin
Source: www.stern.de
